OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
OPKO Health (NASDAQ: OPK) reported third-quarter 2025 results and business highlights on October 29, 2025, including a multi‑program research collaboration with Regeneron using ModeX MSTAR, with potential program milestones >$200M each and overall collaboration value potentially exceeding $1 billion. OPKO completed the sale of BioReference oncology assets to Labcorp for $225 million (including up to $32.5M earnout) and received $173.3M cash at closing. Consolidated Q3 revenue was $151.7M (down from $173.6M); operating income was $48.1M; net income was $21.6M ($0.03 diluted) which included a $101.6M gain on the asset sale. Cash and equivalents were $428.9M; $73.8M of share repurchases completed, $126.2M remaining.
OPKO Health (NASDAQ: OPK) ha riportato i risultati del terzo trimestre 2025 e i punti salienti dell'attività il 29 ottobre 2025, inclusa una collaborazione di ricerca multi-programma con Regeneron che utilizza ModeX MSTAR, con potenziali milestone di programma superiori a 200 milioni di dollari ciascuna e un valore complessivo della collaborazione che potrebbe superare 1 miliardo di dollari. OPKO ha completato la vendita degli asset oncologici BioReference a Labcorp per 225 milioni di dollari (incluso fino a 32,5 milioni di earnout) e ha incassato 173,3 milioni di dollari in contanti al closing. Il fatturato consolidato del Q3 è stato di 151,7 milioni di dollari (in calo rispetto a 173,6 milioni); l'utile operativo è stato di 48,1 milioni di dollari; l'utile netto è stato di 21,6 milioni di dollari (0,03 dollari diluiti) che include un guadagno di 101,6 milioni di dollari dalla vendita dell'asset. Le disponibilità liquide e equivalenti erano di 428,9 milioni di dollari; sono stati completati riacquisti azionari per 73,8 milioni di dollari, restano 126,2 milioni di dollari.
OPKO Health (NASDAQ: OPK) informó los resultados del tercer trimestre de 2025 y los aspectos clave del negocio el 29 de octubre de 2025, incluida una colaboración de investigación multi-programa con Regeneron que utiliza ModeX MSTAR, con hitos potenciales de programa superiores a $200 millones cada uno y un valor total de la colaboración que podría superar $1 mil millones. OPKO completó la venta de activos oncológicos BioReference a Labcorp por $225 millones (incluido hasta $32,5 millones en earnout) y recibió $173,3 millones en efectivo al cierre. Los ingresos consolidados del Q3 fueron $151,7 millones (bajando desde 173,6 millones); la ganancia operativa fue de $48,1 millones; la ganancia neta fue de $21,6 millones ($0,03 por acción diluida) que incluyó una ganancia de $101,6 millones por la venta del activo. Las disponibilidades y equivalentes de efectivo eran de $428,9 millones; se realizaron recompras de acciones por $73,8 millones, quedan $126,2 millones pendientes.
OPKO Health (나스닥: OPK)은 2025년 3분기 실적 및 비즈니스 하이라이트를 2025년 10월 29일 발표했으며, ModeX MSTAR를 사용하는 Regeneron과의 다중 프로그램 연구 협력을 포함합니다. 각 프로그램의 잠재적 이정표는 $200M 이상이며 협력의 총 가치는 $1B를 초과할 수 있습니다. OPKO는 BioReference의 종양학 자산을 Labcorp에 2억2500만 달러에 매각했고(최대 $32.5M의 어너웃 포함) 종료 시점에 현금 $173.3M을 받았습니다. 3분기 연결 매출은 $151.7M로 전년 대비 감소했습니다(173.6M). 영업이익은 $48.1M, 순이익은 $21.6M이고(희석 주당 $0.03) 자산 매각으로 인한 $101.6M의 이익이 포함되어 있습니다. 현금 및 현금성자산은 $428.9M; 자사주 매입은 $73.8M를 완료했고 남은 금액은 $126.2M입니다.
OPKO Health (NASDAQ : OPK) a publié les résultats du troisième trimestre 2025 et les points forts de l’activité le 29 octobre 2025, notamment une collaboration de recherche multi‑programme avec Regeneron utilisant ModeX MSTAR, avec des jalons potentiels de programme supérieurs à 200 millions de dollars chacun et une valeur globale de la collaboration susceptible de dépasser 1 milliard de dollars. OPKO a terminé la vente des actifs oncologiques BioReference à Labcorp pour 225 millions de dollars (y compris jusqu’à 32,5 millions de dollars d’earnout) et a reçu 173,3 millions de dollars en espèces lors de la clôture. Le chiffre d’affaires consolidé du T3 était de 151,7 millions de dollars (en baisse par rapport à 173,6 millions); le résultat opérationnel était de 48,1 millions de dollars; le résultat net était de 21,6 millions de dollars (0,03 dollar dilué) qui incluait un gain de 101,6 millions de dollars sur la vente de l’actif. Les liquidités et équivalents s’élevaient à 428,9 millions de dollars; 73,8 millions de dollars de rachats d’actions ont été réalisés, il en reste 126,2 millions de dollars.
OPKO Health (NASDAQ: OPK) berichtete am 29. Oktober 2025 über die Ergebnisse des dritten Quartals 2025 und Geschäfts-Highlights, darunter eine mehrprogrammige Forschungskooperation mit Regeneron, die ModeX MSTAR nutzt, mit potenziellen Programm-Meilensteinen von jeweils über 200 Mio. USD und einem gesamten Kooperationswert, der potenziell über 1 Milliarde USD liegen könnte. OPKO schloss den Verkauf von BioReference-Onkologievermögenswerten an Labcorp für 225 Mio. USD ab (einschließlich einer Earnout von bis zu 32,5 Mio. USD) und erhielt beim Closing 173,3 Mio. USD in bar. Der konsolidierte Umsatz im Q3 betrug 151,7 Mio. USD (gegenüber 173,6 Mio. USD); operatives Einkommen 48,1 Mio. USD; Nettogewinn 21,6 Mio. USD (0,03 USD verdünnte Anteil) einschließlich eines Gewinns von 101,6 Mio. USD aus dem Asset-Verkauf. Barmittel und Äquivalente betrugen 428,9 Mio. USD; Aktienrückkäufe im Wert von 73,8 Mio. USD abgeschlossen, verbleiben 126,2 Mio. USD.
أعلنت OPKO Health (بورصة ناسداك: OPK) عن نتائج الربع الثالث من عام 2025 ونقاط الأعمال البارزة في 29 أكتوبر 2025، بما في ذلك تعاون بحثي متعدد البرامج مع Regeneron يستخدم ModeX MSTAR، مع آليات مرحلية محتملة تزيد عن 200 مليون دولار لكل برنامج وقيمة إجمالية للتعاون قد تتجاوز مليار دولار. أكملت OPKO بيع أصول الأورام BioReference إلى Labcorp بمبلغ 225 مليون دولار (مشتملاً على حتى 32.5 مليون دولار كEarnout) وتلقت 173.3 مليون دولار نقداً عند الإغلاق. بلغ الإيراد الموحَّد للربع الثالث 151.7 مليون دولار (بانخفاض من 173.6 مليوناً)؛ بلغ الربح التشغيلي 48.1 مليون دولار؛ بلغ صافي الربح 21.6 مليون دولار (0.03 دولار مخفّف للسهم) والذي شمل ربحاً قدره 101.6 مليون دولار من بيع الأصل. كانت النقدية وما يعادلها 428.9 مليون دولار؛ أُنجِز شراء أسهم بمقدار 73.8 مليون دولار، ويبقي 126.2 مليون دولار.
OPKO Health（纳斯达克：OPK）在 2025 年 10 月 29 日公布了 2025 年第三季度业绩及业务要点，其中包括与 Regeneron 使用 ModeX MSTAR 的多项目研究合作， 每个项目的潜在里程碑金额均超过 $200M，而合作的总价值潜在超过 $10 亿。OPKO 已完成向 Labcorp 出售 BioReference 的肿瘤学资产，金额为 $225 million（包括最高至 $32.5 million 的尾铺）并在交割时收到现金 $173.3 million。合并第三季度收入为 $151.7 million（较 173.6 million 下降）；经营利润为 $48.1 million；净利润为 $21.6 million（摊薄后每股 0.03 美元），其中包含来自资产出售的 $101.6 million 的收益。现金及现金等价物为 $428.9 million；完成了价值 $73.8 million 的股票回购，尚余 $126.2 million。
- Regeneron collaboration valued >$1 billion potential
- Upfront/milestone payments >$200M per program
- Completed Labcorp sale for $225M (up to $32.5M earnout)
- Operating income improved to $48.1M in Q3 2025
- Cash and equivalents of $428.9M at Sept 30, 2025
- FDA approved 4Kscore Test without DRE information
- Consolidated revenue down ~12.6% to $151.7M in Q3 2025
- Diagnostics services revenue fell ~21.5% to $95.2M
- Net income included a $101.6M one‑time gain from asset sale
Insights
Large biopharma collaboration and multiple advancing clinical programs materially improve strategic optionality.
OPKO secured a research collaboration with Regeneron Pharmaceuticals using ModeX’s MSTAR platform, with an upfront payment and milestone potential exceeding
Clinical program updates show active progress: a Merck‑partnered Phase 1 Epstein‑Barr virus vaccine with enrollment progressing; first patient dosed in MDX2004 Phase 1/2a; MDX2001 advancing to dose level five with Phase 1b expected in early
Watch the timing and size of Regeneron payments and any announced program opt‑ins or terminations over the next 12–36 months, and monitor clinical readouts for MDX2004 and MDX2001 as near‑term binary catalysts. The arrangement shifts development cost and execution risk to a deep-pocket partner while retaining royalty and milestone economics for OPKO.
Asset sale and operating results strengthened liquidity and lowered diagnostics cost base, but revenue mix shifted downward.
OPKO closed sale of BioReference oncology assets to Labcorp for
Diagnostics services revenue declined to
Key near‑term items to watch include realized earnout amounts from the Labcorp sale, the pace of share repurchases from the stated
Conference call begins at 4:30 p.m. Eastern time today
MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025.
Highlights from the third quarter of 2025 and recent weeks include the following:
- Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several indications. ModeX is entitled to receive an upfront payment and potential milestone payments exceeding
$200 million for each program. The overall value of the collaboration potentially exceeds$1 billion if multiple products from the collaboration are successful. In addition, ModeX is eligible to receive tiered royalties on global net sales, up to low double digits at the highest tier. Regeneron is responsible for funding all preclinical and clinical development, as well as all commercialization activities. - Completed the sale of BioReference Health (BioReference) oncology and related clinical assets to Labcorp for
$225 million . The purchase included$192.5 million that was paid at closing and up to$32.5 million in a performance-based earnout. BioReference will continue to offer its core clinical testing services in the New York and New Jersey region and its 4Kscore® Test franchise, which represented approximately$300 million in revenue for 2024. This transaction streamlines BioReference’s laboratory services business and better positions the company to optimize its test menu and achieve sustained profitability. OPKO intends to utilize a portion of the proceeds to fund its share repurchase program. - Merck advanced the Phase 1 Epstein-Barr virus vaccine trial (NCT06655324). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 healthy adults. Enrollment in this ongoing trial is progressing well and the safety and immunogenicity data obtained from this trial will inform the Phase 2 trial design.
- First patient dosed in MDX2004 Phase 1/2a study for the treatment of advanced cancers (NCT07110584). This study is designed to evaluate the safety, tolerability and biologic activity of MDX2004, a first-in-class trispecific antibody-fusion protein, as an immunotherapy for advanced cancers. Preclinical proof-of-concept data, as well as clinical dose selection analyses to support MDX2004 development will be showcased in two poster presentations at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 5-9, 2025.
- Abstract for MDX-2001 CMet-Trop2/CD3-CD28, a first-in-class tetraspecific T-cell engager, was presented at ESMO 2025. In October, the abstract titled “A phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors” was presented at ESMO Congress 2025, the annual meeting of the European Society for Medical Oncology. The MDX2001 CMet-Trop2/CD3-CD28 tetraspecific antibody has advanced to the fifth dose level in its Phase 1 clinical trial, with Phase 1b studies in select solid tumors expected to begin in early 2026.
- Abstract for first-in-class dual GLP-1/glucagon tablet candidate was presented at the ENDO 2025 annual meeting. In July, the abstract titled “First-in-Class Oral Dual GLP-1/Glucagon Agonist for Patients with Obesity and Metabolic Disorders: In Vivo Pharmacokinetic and Pharmacodynamic Results” highlighting preclinical animal data was presented at ENDO 2025, the annual meeting of the Endocrine Society. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera Bio (Entera) whereby the companies are advancing a proprietary novel dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment with OPK-88006 and Entera’s proprietary N-Tab™ technology.
- Abstract on the pharmacokinetics/pharmacodynamics of oral GLP-2 tablet for the treatment of short bowel syndrome was presented at the 2025 ESPEN Congress. In September, the abstract “A First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” highlighting in vivo animal data was presented at the 47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress. Pursuant to a research collaboration agreement with Entera, the companies are developing an oral GLP-2 tablet that combines a proprietary long-acting GLP-2 agonist developed by OPKO with Entera’s proprietary N-Tab™ technology, for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption.
- FDA approved the supplemental application for the 4Kscore® Test regarding the availability of digital rectal examination information. In July, the U.S. Food and Drug Administration (FDA) approved OPKO’s supplemental application enabling the performance of the 4Kscore® Test without digital rectal examination (DRE) information. The 4Kscore® Test is indicated for the assessment of the likelihood of aggressive prostate cancer in men age 45 and older who have age-specific elevated/abnormal screening PSA results. Two prospective controlled clinical studies (n=937) concluded that the 4Kscore® Test is a reliable (>
96% sensitivity and accuracy) blood test to assess the probability of aggressive prostate cancer, before biopsy decisions. In the U.S., over90% of PSA screening tests are ordered by primary care providers, potential users of the 4Kscore® Test who don’t routinely perform a DRE.
Third Quarter Financial Results
- Consolidated: Consolidated total revenues for the third quarter of 2025 were
$151.7 million compared with$173.6 million for the comparable period of 2024. Operating income for the third quarter of 2025 was$48.1 million compared with$14.2 million for the 2024 quarter. Net income for the third quarter of 2025 included a gain of$101.6 million from the sale of the BioReference oncology assets. The prior-year period included a gain of$121.5 million from the sale of certain BioReference clinical assets and income of$45.9 million related to the investment in GeneDx shares. Net income for the third quarter of 2025 was$21.6 million , or$0.03 per diluted share, compared with$24.9 million , or$0.03 per diluted share, for the 2024 quarter. - Pharmaceuticals: Revenue from products in the third quarter of 2025 was
$37.7 million compared with$39.1 million in the third quarter of 2024, reflecting lower sales volumes in certain international operations primarily due to the timing of customer orders and product mix, partially offset by an increase in Rayaldee sales. Revenue from sales of Rayaldee was$7.5 million compared with$5.8 million in the comparable prior-year period. Revenue from the transfer of intellectual property and other was$18.8 million in the third quarter of 2025 compared with$13.2 million in the 2024 period. The increase was driven by higher revenue from the BARDA contract and higher gross profit share payments for NGENLA, which totaled$8.8 million in the 2025 period compared with$7.0 million in the 2024 period. Total costs and expenses decreased to$80.6 million in the third quarter of 2025 from$84.6 million in the prior-year period, primarily due to lower cost of revenue related to lower sales volume and reduced employee-related expense, partially offset by higher research and development expenses driven by progress in the BARDA collaboration and advancements in early-stage programs. Operating loss was$24.2 million in the third quarter of 2025 compared with$32.2 million in the third quarter of 2024, with both periods including$18.0 million of depreciation and amortization expense. - Diagnostics: Revenue from services in the third quarter of 2025 was
$95.2 million compared with$121.3 million in the prior-year period, with the decrease primarily due to lower clinical test volume principally as a result of the sale of certain BioReference assets in 2024, partially offset by higher clinical test reimbursement rates. Total costs and expenses, net of the gain on the sale of assets in both periods, were$13.6 million in the third quarter of 2025 compared with$62.7 million in the third quarter of 2024. The decrease was primarily attributable to the assets sold and continued cost-reduction initiatives at BioReference. Operating income was$81.6 million in the third quarter of 2025, which included$4.7 million of depreciation and amortization expense, compared with$58.5 million in the 2024 period, which included$6.1 million of depreciation and amortization expense. The third quarter of 2025 included revenue of$19.5 million and costs and expenses of$25.2 million from the oncology assets that were sold to Labcorp on September 15, 2025. - Cash, cash equivalents, marketable securities and restricted cash: Cash, cash equivalents and restricted cash were
$428.9 million as of September 30, 2025. In September 2025, OPKO received$173.3 million in cash consideration and an escrow of$19.2 million subject to any outstanding indemnity claims upon closing of the Labcorp transaction. As of September 30, 2025, approximately$73.8 million of OPKO’s common stock had been repurchased under the program since its authorization in July 2024, and approximately$126.2 million remains authorized and available for future repurchases.
Conference Call and Webcast Information
OPKO’s senior management will provide a business update, discuss third quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time. Participants are encouraged to pre-register for the conference call here. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here.
A telephone replay will be available until November 5, 2025, by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 8678248. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance and expectations regarding the market for and sales of our products, whether the collaboration with Regeneron will be successful and whether we will receive milestone payments and/or royalties as a result of that collaboration, whether the remaining BioReference business will become profitable, whether the approved supplemental application for 4Kscore will further increase use of the test without DRE information, whether we will be able to submit Investigational New Drug applications for the oral and subcutaneous forms of GLP-1/glucagon and GLP-2 tablet and the timing of those submissions, whether we will have a successful collaboration with Entera, whether our product development efforts will be successful and whether the expected benefits of our products will be realized, including whether the data for MDX2004 will be positive, whether preclinical data will be indicative of clinical data should any of our preclinical programs progress into clinical development, whether the trial for MDX2001 and EBV will continue to progress and whether the data will be positive for all trials, including the EBV Vaccine trial, whether we will receive additional funding from BARDA, whether the relationship with our commercial and strategic partners will be successful, whether our commercial and strategic partners will be able to commercialize our products and successfully utilize our technologies, whether our partner will be able to continue to successfully commercialize NGENLA and the NGENLA profits will provide adequate upside, whether we will continue to repurchase shares under a buyback program, our ability to market and sell any of our products in development, whether we will continue to successfully advance products in our pipeline and whether they can be commercialized, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and under the heading “Risk Factors” in our other filings with the Securities and Exchange Commission, as well as the continuation and success of our relationship with our commercial partners, liquidity issues and the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Contacts:
Alliance Advisors IR
Yvonne Briggs, 310-691-7100
ybriggs@allianceadvisors.com
or
Bruce Voss, 310-691-7100
bvoss@allianceadvisors.com
—Tables to Follow—
| OPKO Health, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in millions) Unaudited | |||||||
| As of | |||||||
| September 30, 2025 | December 31, 2024 | ||||||
| Assets: | |||||||
| Cash and cash equivalents | $ | 415.2 | $ | 431.9 | |||
| Accounts receivable, net | 94.6 | 118.0 | |||||
| Inventory, net | 65.0 | 56.8 | |||||
| Other current assets and prepaid expenses | 52.4 | 55.4 | |||||
| Total current assets | 627.2 | 662.1 | |||||
| In-process research and development and goodwill | 679.0 | 724.3 | |||||
| Other assets | 689.3 | 813.8 | |||||
| Total Assets | $ | 1,995.5 | $ | 2,200.2 | |||
| Liabilities and Equity: | |||||||
| Accounts payable | $ | 50.8 | $ | 47.1 | |||
| Accrued expenses | 95.6 | 118.4 | |||||
| Current portion of convertible notes | 0.0 | 0.2 | |||||
| Other current liabilities | 22.9 | 27.4 | |||||
| Total current liabilities | 169.3 | 193.1 | |||||
| Long-term portion of convertible notes | 82.7 | 173.6 | |||||
| Senior secured notes | 246.2 | 245.6 | |||||
| Deferred tax liabilities, net | 130.3 | 140.8 | |||||
| Other long-term liabilities, principally leases | 61.5 | 81.7 | |||||
| Total Liabilities | 690.0 | 834.8 | |||||
| Equity | 1,305.5 | 1,365.4 | |||||
| Total Liabilities and Equity | $ | 1,995.5 | $ | 2,200.2 | |||
| OPKO Health, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in millions, except share and per share data) Unaudited | ||||||||||||||||
| For the three months ended September 30, | For the nine months ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues | ||||||||||||||||
| Revenue from services | $ | 95.2 | $ | 121.3 | $ | 299.2 | $ | 377.5 | ||||||||
| Revenue from products | 37.7 | 39.1 | 113.2 | 117.7 | ||||||||||||
| Revenue from transfer of intellectual property and other | 18.8 | 13.2 | 46.0 | 34.3 | ||||||||||||
| Total revenues | 151.7 | 173.6 | 458.4 | 529.5 | ||||||||||||
| Costs and expenses | ||||||||||||||||
| Cost of service revenues | 80.4 | 108.8 | 247.3 | 325.8 | ||||||||||||
| Cost of product revenues | 21.4 | 24.7 | 69.2 | 69.8 | ||||||||||||
| Selling, general and administrative | 53.8 | 98.2 | 172.5 | 237.2 | ||||||||||||
| Research and development | 30.1 | 28.8 | 91.3 | 74.8 | ||||||||||||
| Amortization of intangible assets | 19.5 | 20.4 | 58.8 | 62.3 | ||||||||||||
| Gain on sale of assets | (101.6 | ) | (121.5 | ) | (101.6 | ) | (121.5 | ) | ||||||||
| Total costs and expenses | 103.6 | 159.4 | 537.5 | 648.4 | ||||||||||||
| Operating Income (loss) | 48.1 | 14.2 | (79.1 | ) | (118.9 | ) | ||||||||||
| Other expense (income), net | (6.7 | ) | 34.2 | (115.4 | ) | 73.6 | ||||||||||
| Income (loss) before income taxes and investment losses | 41.4 | 48.4 | (194.5 | ) | (45.3 | ) | ||||||||||
| Income tax (provision) benefit | (19.8 | ) | (23.5 | ) | 0.1 | (21.9 | ) | |||||||||
| Income (loss) before investment losses | 21.6 | 24.9 | (194.4 | ) | (67.2 | ) | ||||||||||
| Loss from investments in investees | (0.0 | ) | (0.0 | ) | (0.0 | ) | (0.0 | ) | ||||||||
| Net income (loss) | $ | 21.6 | $ | 24.9 | $ | (194.4 | ) | $ | (67.2 | ) | ||||||
| Income (loss) per share, basic | $ | 0.03 | $ | 0.04 | $ | (0.26 | ) | $ | (0.10 | ) | ||||||
| Income (loss) per share, diluted | $ | 0.03 | $ | 0.03 | $ | (0.26 | ) | $ | (0.10 | ) | ||||||
| Weighted average common shares outstanding, basic | 777,154,808 | 694,622,466 | 746,136,135 | 699,675,944 | ||||||||||||
| Weighted average common shares outstanding, diluted | 779,919,259 | 998,363,636 | 746,136,135 | 699,675,944 | ||||||||||||
FAQ
What did OPKO (OPK) announce on October 29, 2025 about Regeneron?
How much did OPKO receive from the Labcorp sale reported October 29, 2025?
What were OPKO’s Q3 2025 revenues and net income (OPK)?
How much cash did OPKO report on Sept 30, 2025 and what buyback progress was disclosed?
What change did the FDA make regarding OPKO’s 4Kscore Test in 2025?
How did OPKO’s diagnostics revenue perform in Q3 2025 (OPK)?
